Latest news
RLMD: Strong cash position and robust NDV-01 phase II results set stage for late-stage trials in 2026 - TradingViewTradingView · Thu, 06 Aug 2026 21:59:56 GMTRelmada Therapeutics (Nasdaq: RLMD) details Q2 2026 loss and NDV-01 Phase 3 path - Stock TitanStock Titan · Thu, 06 Aug 2026 20:41:35 GMTRLMD: Advanced clinical pipeline and robust cash position support operations through 2029 - TradingViewTradingView · Thu, 06 Aug 2026 20:29:06 GMTRelmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswireGlobeNewswire · Thu, 06 Aug 2026 20:05:00 GMTPress Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - MoomooMoomoo · Thu, 06 Aug 2026 20:05:00 GMTRelmada Therapeutics Appoints New Chief Business Officer - The Globe and MailThe Globe and Mail · Wed, 29 Jul 2026 07:00:00 GMTRelmada Therapeutics Appoints Bipin Dalmia as Chief Business Officer to Advance NDV-01 and Corporate Growth - Quiver QuantitativeQuiver Quantitative · Tue, 28 Jul 2026 12:45:00 GMTRelmada hires executive with U.S. bladder cancer gene therapy experience - Stock TitanStock Titan · Tue, 28 Jul 2026 12:30:00 GMT